These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 29427492

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Chronic liver disease and oxidative stress - a narrative review.
    Seen S.
    Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1021-1035. PubMed ID: 34176419
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
    Polyzos SA, Kountouras J, Mantzoros CS, Polymerou V, Katsinelos P.
    Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101
    [Abstract] [Full Text] [Related]

  • 47. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
    Lazaridis N, Tsochatzis E.
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
    [Abstract] [Full Text] [Related]

  • 48. Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?
    Goossens N, Hoshida Y.
    Gastroenterology; 2016 Jun; 150(8):1710-7. PubMed ID: 26784140
    [No Abstract] [Full Text] [Related]

  • 49. Gut Microbiota and Complications of Liver Disease.
    Acharya C, Bajaj JS.
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [Abstract] [Full Text] [Related]

  • 50. Burden of non-alcoholic fatty liver disease in Australia.
    Mahady SE, Adams LA.
    J Gastroenterol Hepatol; 2018 Jun; 33 Suppl 1():1-11. PubMed ID: 29851153
    [Abstract] [Full Text] [Related]

  • 51. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA.
    BMC Gastroenterol; 2015 Dec 03; 15():169. PubMed ID: 26635079
    [Abstract] [Full Text] [Related]

  • 52. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
    Huang W, Zhang XX.
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb 20; 25(2):157-160. PubMed ID: 28297806
    [Abstract] [Full Text] [Related]

  • 53. Review article: new treatments in non-alcoholic fatty liver disease.
    Townsend SA, Newsome PN.
    Aliment Pharmacol Ther; 2017 Sep 20; 46(5):494-507. PubMed ID: 28677333
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Current management of non-alcoholic fatty liver disease.
    Lisboa QC, Costa SM, Couto CA.
    Rev Assoc Med Bras (1992); 2016 Dec 20; 62(9):872-878. PubMed ID: 28001263
    [Abstract] [Full Text] [Related]

  • 56. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J.
    Oncotarget; 2016 Jul 05; 7(27):42762-42776. PubMed ID: 27072576
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Nonalcoholic fatty liver disease: new treatments.
    Hardy T, Anstee QM, Day CP.
    Curr Opin Gastroenterol; 2015 May 05; 31(3):175-83. PubMed ID: 25774446
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.